In Brief: Sarepta Filing Delay; Baxter Hemophilia Approval; Valeant To Increase Allergan Offer
This article was originally published in The Pink Sheet Daily
Executive Summary
Sarepta says NDA submission for its muscular dystrophy treatment will be delayed until mid-2015 due to “new” and “updated” FDA requirements; agency approves Baxter’s porcine-sourced Obizur for acquired hemophilia A.